RDHL
Income statement / Annual
Last year (2024), RedHill Biopharma Ltd.'s total revenue was $8.04 M,
an increase of 23.17% from the previous year.
In 2024, RedHill Biopharma Ltd.'s net income was -$8.27 M.
See RedHill Biopharma Ltd.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$8.04 M |
$6.53 M |
$61.80 M |
$85.76 M |
$64.36 M |
$6.29 M |
$8.36 M |
$4.01 M |
$101.00 K |
$3.00 K |
| Cost of Revenue |
$3.19 M
|
$3.46 M
|
$33.34 M
|
$49.41 M
|
$36.89 M
|
$2.26 M
|
$2.84 M
|
$2.13 M
|
$30.54 M
|
$22.00 M
|
| Gross Profit |
$4.85 M
|
$3.07 M
|
$28.46 M
|
$36.35 M
|
$27.47 M
|
$4.03 M
|
$5.52 M
|
$1.88 M
|
-$30.44 M
|
-$22.00 M
|
| Gross Profit Ratio |
0.6
|
0.47
|
0.46
|
0.42
|
0.43
|
0.64
|
0.66
|
0.47
|
-301.41
|
-7333
|
| Research and Development Expenses |
$1.59 M
|
$3.53 M
|
$7.28 M
|
$29.50 M
|
$16.49 M
|
$17.42 M
|
$24.86 M
|
$32.97 M
|
$25.24 M
|
$17.77 M
|
| General & Administrative Expenses |
$14.52 M
|
$28.88 M
|
$54.97 M
|
$76.60 M
|
$25.38 M
|
$11.48 M
|
$7.51 M
|
$8.03 M
|
$5.16 M
|
$3.99 M
|
| Selling & Marketing Expenses |
$1.00 M
|
$2.10 M
|
$9.06 M
|
$11.39 M
|
$49.29 M
|
$18.33 M
|
$12.49 M
|
$12.01 M
|
$242.00 K
|
$149.00 K
|
| Selling, General & Administrative Expenses |
$15.52 M
|
$30.98 M
|
$64.03 M
|
$87.99 M
|
$74.66 M
|
$29.81 M
|
$19.99 M
|
$20.04 M
|
$5.40 M
|
$4.13 M
|
| Other Expenses |
$2.36 M
|
-$44.06 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$845.00 K
|
$0.00
|
$100.00 K
|
| Operating Expenses |
$19.46 M
|
-$9.56 M
|
$71.31 M
|
$117.49 M
|
$91.15 M
|
$47.23 M
|
$44.85 M
|
$53.85 M
|
$30.64 M
|
$22.01 M
|
| Cost And Expenses |
$22.66 M
|
-$6.10 M
|
$104.64 M
|
$166.89 M
|
$128.04 M
|
$49.49 M
|
$47.69 M
|
$55.98 M
|
$30.64 M
|
$22.01 M
|
| Interest Income |
$133.00 K
|
$94.00 K
|
$140.00 K
|
$51.00 K
|
$176.00 K
|
$444.43 K
|
$678.00 K
|
$6.51 M
|
$282.00 K
|
$236.00 K
|
| Interest Expense |
$55.00 K
|
$367.00 K
|
$41.33 M
|
$16.57 M
|
$12.45 M
|
$439.42 K
|
$167.00 K
|
$77.00 K
|
$7.00 K
|
$12.00 K
|
| Depreciation & Amortization |
$619.00 K
|
$1.99 M
|
$8.15 M
|
$18.15 M
|
$8.75 M
|
$1.21 M
|
$90.00 K
|
$81.00 K
|
$44.00 K
|
$36.00 K
|
| EBITDA |
-$7.59 M |
$26.27 M |
-$22.18 M |
-$63.03 M |
-$54.98 M |
-$40.70 M |
-$38.73 M |
-$45.46 M |
-$30.50 M |
-$21.97 M |
| EBITDA Ratio |
-0.94
|
4.02
|
-0.36
|
-0.73
|
-0.85
|
-6.47
|
-4.63
|
-11.35
|
-301.97
|
-7322
|
| Operating Income Ratio |
-1.82
|
1.93
|
-0.69
|
-0.95
|
-0.99
|
-6.87
|
-4.7
|
-12.97
|
-302.41
|
-7334
|
| Total Other Income/Expenses Net |
$6.35 M
|
$11.28 M
|
-$28.83 M
|
-$16.61 M
|
-$12.49 M
|
$897.00 K
|
$511.00 K
|
$6.43 M
|
$1.17 M
|
$812.00 K
|
| Income Before Tax |
-$8.27 M
|
$23.92 M
|
-$71.67 M
|
-$97.74 M
|
-$76.17 M
|
-$42.30 M
|
-$38.82 M
|
-$45.54 M
|
-$29.37 M
|
-$21.09 M
|
| Income Before Tax Ratio |
-1.03
|
3.66
|
-1.16
|
-1.14
|
-1.18
|
-6.72
|
-4.64
|
-11.37
|
-290.79
|
-7030
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$8.27 M
|
$23.92 M
|
-$71.67 M
|
-$97.74 M
|
-$76.17 M
|
-$42.30 M
|
-$38.82 M
|
-$45.54 M
|
-$29.37 M
|
-$21.09 M
|
| Net Income Ratio |
-1.03
|
3.66
|
-1.16
|
-1.14
|
-1.18
|
-6.72
|
-4.64
|
-11.37
|
-290.79
|
-7030
|
| EPS |
-7 |
46 |
-600 |
-1000 |
-1000 |
-700 |
-850 |
-1300 |
-1100 |
-950 |
| EPS Diluted |
-7 |
46 |
-600 |
-1000 |
-1000 |
-700 |
-850 |
-1300 |
-1100 |
-950 |
| Weighted Average Shares Out |
$2.46 M
|
$518.24 K
|
$123.86 K
|
$93.05 K
|
$72.85 K
|
$59.38 K
|
$46.24 K
|
$35.31 K
|
$25.70 K
|
$22.16 K
|
| Weighted Average Shares Out Diluted |
$2.46 M
|
$518.24 K
|
$123.86 K
|
$93.05 K
|
$72.85 K
|
$59.38 K
|
$46.24 K
|
$35.31 K
|
$25.76 K
|
$22.34 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
